IDH2 and glioma: Notably, within gliomas, we can divide these molecular biomarkers into those with a point mutation in the IDH1 or IDH2 gene (IDH-mutant), which occurs predominantly in lower-grade gliomas (WHO grade II/III), or else into secondary GBM with no mutation (IDH-wildtype).